SensoGenic

Company Overview

Snapshot

Founded in January 2018 by Oded Shoseyov and Alon Yasovsky, SensoGenic operates with 1–10 employees. The company has secured $776.6K in total capital across two funding rounds. In March 2018, SensoGenic received seed funding from eHealth Ventures.

Business overview

SensoGenic is a Health Tech & Life Sciences company focused on developing a consumer biosensor for allergen detection. The company's core technology leverages patented molecule-allergen interaction and electronic detection to provide a comprehensive solution for individuals managing food allergies. Operating within the Digital Healthcare sector, SensoGenic aims to serve patients globally with its innovative diagnostic tools.

Strategic signal

In June 2022, SensoGenic ceased operations, indicating a significant shift in its corporate trajectory. This cessation sends a strong signal to investors and the market about the company's inability to continue its development and commercialization efforts for its allergen detection biosensor.

Company Intelligence Q&A

What is SensoGenic's primary focus?

SensoGenic is developing a consumer biosensor based on patented molecule-allergen interaction and electronic detection technology, aiming to provide a comprehensive solution for people suffering from food allergies.

When was SensoGenic founded and by whom?

SensoGenic was founded in January 2018 by Oded Shoseyov and Alon Yasovsky.

What was the company's status as of June 2022?

As of June 2022, SensoGenic ceased to operate and is classified as Non Active.

Has SensoGenic received any funding?

SensoGenic has raised $776.6K in total capital across two funding rounds. In March 2018, the company received seed funding from eHealth Ventures.

What was a notable product development for SensoGenic?

In June 2019, SensoGenic was featured for its new handheld sensor designed to alert people to allergens in food.